A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

J Overgaard; H S Hansen; M Overgaard; Lars Bastholt; A Berthelsen; L Specht; B Lindeløv; K Jørgensen

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

J Overgaard, H S Hansen, M Overgaard, Lars Bastholt, A Berthelsen, L Specht, B Lindeløv, K Jørgensen

Afdeling for Klinisk Fysiologi og Nuklearmedicin DIA

550 Citationer (Scopus)

Abstract

A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx.

Originalsprog	Engelsk
Tidsskrift	Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Vol/bind	46
Udgave nummer	2
Sider (fra-til)	135-46
Antal sider	12
Status	Udgivet - 1 feb. 1998

Fingeraftryk

Dyk ned i forskningsemnerne om 'A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85'. Sammen danner de et unikt fingeraftryk.

Citationsformater

Overgaard, J., Hansen, H. S., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., Lindeløv, B., & Jørgensen, K. (1998). A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 46(2), 135-46.

A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. / Overgaard, J; Hansen, H S; Overgaard, M et al.
I: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, Bind 46, Nr. 2, 01.02.1998, s. 135-46.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

Overgaard, J, Hansen, HS, Overgaard, M, Bastholt, L, Berthelsen, A, Specht, L, Lindeløv, B & Jørgensen, K 1998, 'A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85', Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, bind 46, nr. 2, s. 135-46.

Overgaard J, Hansen HS, Overgaard M, Bastholt L, Berthelsen A, Specht L et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1998 feb. 1;46(2):135-46.

Overgaard, J ; Hansen, H S ; Overgaard, M et al. / A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. I: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 1998 ; Bind 46, Nr. 2. s. 135-46.

@article{b5af8f611ff64eef8bb66d6269e1a5e7,

title = "A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85",

abstract = "A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx.",

author = "J Overgaard and Hansen, {H S} and M Overgaard and Lars Bastholt and A Berthelsen and L Specht and B Lindel{\o}v and K J{\o}rgensen",

year = "1998",

month = feb,

day = "1",

language = "English",

volume = "46",

pages = "135--46",

journal = "Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology",

issn = "1879-0887",

publisher = "Elsevier Ireland Ltd",

number = "2",

}

TY - JOUR

T1 - A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85

AU - Overgaard, J

AU - Hansen, H S

AU - Overgaard, M

AU - Bastholt, Lars

AU - Berthelsen, A

AU - Specht, L

AU - Lindeløv, B

AU - Jørgensen, K

PY - 1998/2/1

Y1 - 1998/2/1

N2 - A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx.

AB - A multicenter randomized and balanced double-blind trial with the objective of assessing the efficacy and tolerance of nimorazole given as a hypoxic radiosensitizer in conjunction with primary radiotherapy of invasive carcinoma of the supraglottic larynx and pharynx.

M3 - Journal article

C2 - 9510041

SN - 1879-0887

VL - 46

SP - 135

EP - 146

JO - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

JF - Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology

IS - 2

ER -